In March 2020, Allergan received FDA approval for DURYSTA™ (bimatoprost implant) the first and only Intracameral Biodegradable Sustained-Release implant to lower intraocular pressure in Open-Angle ...

Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...

California-based ophthalmic firm, Glaukos, confirmed that its iDose travoprost intracameral implant (TR ... of the platform loaded with the drug bimatoprost during cataract surgery in patients ...